Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Case Report: Nontuberculous mycobacterial infections in children with complete DiGeorge anomaly.

Frontiers in immunology·2023

Same author

Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor.

Case reports in urology·2021

Same author

The human gastrointestinal microbiota and prostate cancer development and treatment.

Investigative and clinical urology·2020

Same author

Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer.

Urologic oncology·2019

Same author

Antibiotic resistance, hospitalizations, and mortality related to prostate biopsy: first report from the Norwegian Patient Registry.

World journal of urology·2019

Same author

Metagenomics in diagnosis and improved targeted treatment of UTI.

World journal of urology·2019

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Focal therapy for prostate cancer: pathologic basis.

Vladimir Mouraviev¹, John F Madden

¹Division of Urologic Surgery, Department of Surgery, Duke Prostate Center, Durham, NC, USA.

Current Opinion in Urology

|February 4, 2009

Summary

Focal therapy for prostate cancer requires careful patient selection due to multifocal disease. Advanced imaging and biopsy techniques are crucial for accurate tumor mapping and treatment planning.

More Related Videos

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Experiment Videos

Last Updated: Jun 26, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Area of Science:

Urology
Oncology
Pathology

Background:

Prostate cancer often presents as multifocal lesions.
Early diagnosis identifies patients with unifocal or low-volume disease.
Focal therapy offers an alternative to whole-gland treatments.

Purpose of the Study:

To review pathologic features of low-volume, low-risk prostate cancer.
To inform patient selection for focal prostate cancer therapy.
To guide treatment strategies as an alternative to radical treatments.

Main Methods:

Review of existing literature on prostate cancer pathology and focal therapy.
Analysis of criteria for patient selection in focal treatment protocols.
Discussion of imaging and biopsy techniques for tumor localization.

Main Results:

Prostate cancer is typically multifocal, but early detection reveals unifocal/low-volume cases.
Partial-gland ablation is a potential future treatment for early-stage prostate cancer.
Accurate tumor mapping is essential for parenchyma-preserving ablation.

Conclusions:

Patient selection for focal therapy, including hemiablation, is challenging due to imperfect correlation of tumor characteristics.
Extended, imaging-guided multicore biopsy protocols may be necessary for precise tumor mapping.
Further research into molecular markers and advanced imaging is needed to optimize patient selection and focal treatment strategies.